Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 551

1.

A response to "Personalised medicine and population health: breast and ovarian cancer".

Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E.

Hum Genet. 2019 Mar;138(3):287-289. doi: 10.1007/s00439-019-01984-z. Epub 2019 Feb 27. No abstract available.

PMID:
30810870
2.

Prediction of reader estimates of mammographic density using convolutional neural networks.

Ionescu GV, Fergie M, Berks M, Harkness EF, Hulleman J, Brentnall AR, Cuzick J, Evans DG, Astley SM.

J Med Imaging (Bellingham). 2019 Jul;6(3):031405. doi: 10.1117/1.JMI.6.3.031405. Epub 2019 Jan 31.

PMID:
30746393
3.

The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing.

Lo LL, Collins IM, Bressel M, Butow P, Emery J, Keogh L, Weideman P, Steel E, Hopper JL, Trainer AH, Mann GB, Bickerstaffe A, Antoniou AC, Cuzick J, Phillips KA.

JMIR Form Res. 2018 Nov 7;2(2):e24. doi: 10.2196/formative.9935.

4.

Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry.

Beltran L, Ahmad AS, Sandu H, Kudahetti S, Soosay G, Møller H, Cuzick J, Berney DM; Transatlantic Prostate Group.

Am J Surg Pathol. 2019 Mar;43(3):361-368. doi: 10.1097/PAS.0000000000001202.

PMID:
30531531
5.

Competing Risks for a Diagnosis of Invasive Breast Cancer-Reply.

Brentnall AR, Buist DSM, Cuzick J.

JAMA Oncol. 2019 Jan 1;5(1):111. doi: 10.1001/jamaoncol.2018.5102. No abstract available.

PMID:
30452738
6.

Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention.

Pegington M, Evans DG, Howell A, Donnelly LS, Wiseman J, Cuzick JM, Harvie MN.

Eur J Cancer Prev. 2018 Nov 15. doi: 10.1097/CEJ.0000000000000493. [Epub ahead of print]

PMID:
30444752
7.

Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.

Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, Smith LW, van Niekerk DJ, Ogilvie GS, Coldman AJ, Warman R, Reuter C, Cuzick J, Lorincz AT.

Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31976. [Epub ahead of print]

PMID:
30412281
8.

Outcome measures in clinical trials of treatments for acute severe haemorrhage.

Brenner A, Arribas M, Cuzick J, Jairath V, Stanworth S, Ker K, Shakur-Still H, Roberts I.

Trials. 2018 Oct 1;19(1):533. doi: 10.1186/s13063-018-2900-4.

9.

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q, Cuzick J, Dowsett M.

Breast Cancer Res. 2018 Sep 4;20(1):103. doi: 10.1186/s13058-018-1040-9.

10.

Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.

Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL.

Elife. 2018 Sep 4;7. pii: e37294. doi: 10.7554/eLife.37294.

11.

Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.

Lo LL, Milne RL, Liao Y, Cuzick J, Terry MB, Phillips KA.

Br J Cancer. 2018 Jul;119(1):36-39. doi: 10.1038/s41416-018-0120-z. Epub 2018 Jun 21.

PMID:
29925933
12.

Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds.

Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S.

Breast Cancer Res. 2018 Jun 8;20(1):49. doi: 10.1186/s13058-018-0979-x.

13.

Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively.

Ahmad AS, Parameshwaran V, Beltran L, Fisher G, North BV, Greenberg D, Soosay G, Møller H, Scardino P, Cuzick J, Berney DM; Transatlantic Prostate Group.

Oncotarget. 2018 Apr 17;9(29):20555-20562. doi: 10.18632/oncotarget.24994. eCollection 2018 Apr 17.

14.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Oct 1;29(10):2153. doi: 10.1093/annonc/mdx806. No abstract available.

PMID:
29733336
15.

Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.

Hackett J, Thorneloe R, Side L, Wolf M, Horne R, Cuzick J, Smith SG.

Breast Cancer Res Treat. 2018 Aug;170(3):633-640. doi: 10.1007/s10549-018-4775-1. Epub 2018 Apr 24.

16.

Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.

Cuzick J.

Br J Cancer. 2018 May;118(9):1155-1161. doi: 10.1038/s41416-018-0039-4. Epub 2018 Apr 23. Review.

PMID:
29681616
17.

Molecular progression to cervical precancer, epigenetic switch or sequential model?

Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, Boer S, Cuzick J, Lorincz AT.

Int J Cancer. 2018 Apr 21. doi: 10.1002/ijc.31549. [Epub ahead of print]

18.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J.

J Clin Oncol. 2018 Jul 1;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20.

19.

Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.

Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J.

Urol Oncol. 2018 Jun;36(6):310.e7-310.e13. doi: 10.1016/j.urolonc.2018.03.011. Epub 2018 Apr 11.

PMID:
29655620
20.

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density.

Brentnall AR, Cuzick J, Buist DSM, Bowles EJA.

JAMA Oncol. 2018 Sep 1;4(9):e180174. doi: 10.1001/jamaoncol.2018.0174. Epub 2018 Sep 13.

Supplemental Content

Loading ...
Support Center